Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
25.29
-1.01 (-3.84%)
Apr 28, 2025, 4:00 PM EDT - Market closed
AAPG Revenue
In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M CNY with 341.77% growth. Ascentage Pharma Group International had revenue of 156.90M in the half year ending December 31, 2024, with 37.70% growth.
Revenue (ttm)
980.65M CNY
Revenue Growth
+341.77%
P/S Ratio
16.22
Revenue / Employee
1,729,541 CNY
Employees
567
Market Cap
2.18B undefined
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
AAPG News
- 17 hours ago - Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax - GlobeNewsWire
- 5 days ago - Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin - GlobeNewsWire
- 4 weeks ago - Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan - Benzinga
- 4 weeks ago - Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 6 weeks ago - Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 - GlobeNewsWire
- 7 weeks ago - Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) - GlobeNewsWire
- 2 months ago - Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares - GlobeNewsWire
- 3 months ago - Ascentage Pharma Announces Closing of U.S. Initial Public Offering - GlobeNewsWire